Last reviewed: June 26, 2026
Last updated: June 26, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide pens deliver medication through a carefully structured dose escalation protocol that typically begins at 0.25 mg and advances over 16 weeks to a maintenance dose of 2.4 mg. Understanding how these doses progress helps you prepare for your weight loss treatment and recognize what changes to expect during your first few months of therapy.
How Semaglutide Injection Doses Progress Over Time
A standard semaglutide dosing schedule follows a four-week escalation pattern, sometimes called a dose titration protocol. Week one through four uses 0.25 mg, week five through eight increases to 0.5 mg, week nine through twelve moves to 1.0 mg, week thirteen through sixteen reaches 1.7 mg, and week seventeen onward settles at the standard 2.4 mg maintenance dose. This gradual approach gives your gastrointestinal system time to adjust to the medication's effects on appetite signaling.
Not every patient follows the exact same timeline. Some individuals reach their effective dose at 1.7 mg and choose to remain there rather than advancing to 2.4 mg. Others may pause at an intermediate dose if side effects arise, then continue upward once their body adapts. Your prescribing provider adjusts the schedule based on your tolerance, weight loss progress, and individual health factors.
What Each Semaglutide Dose Level Does to Appetite
At 0.25 mg and 0.5 mg, most patients notice early appetite suppression and slower gastric emptying, the process controlling how quickly food leaves your stomach. By the time you reach 1.0 mg to 1.7 mg, the appetite-suppressing effects become more pronounced, with many people reporting significantly reduced hunger between meals and smaller portion sizes at eating times. The 2.4 mg maintenance dose represents the highest dose studied in clinical trials for weight loss and produces sustained appetite control for most patients.
Individual response varies widely depending on your genetic predisposition to GLP-1 receptor sensitivity. PlexusDx's Precision Peptide Genetic Test identifies your genetic variants in the GLP1R gene and other appetite-regulation pathways, allowing your provider to predict whether you might respond optimally at a lower dose or benefit from advancing to the full 2.4 mg target.
PlexusDx Flat Pricing: Your Dose Goes Up, Not Your Cost
PlexusDx compounded semaglutide injection starts at $149 per month across all three commitment tiers. Whether you inject 0.25 mg or 2.4 mg, your monthly cost remains unchanged—a transparent pricing model designed to remove financial barriers as your treatment progresses. This flat-price approach means you never face a surprise bill when your provider increases your dose.
All PlexusDx medications come from licensed 503A compounding pharmacies and are available in all 50 states without insurance requirements or membership fees. Patients can use HSA or FSA funds to pay for their monthly supply, and treatment begins after your first provider consultation.
Comparing Injection Doses to Oral Semaglutide Tablets
PlexusDx offers both injectable and oral forms of semaglutide. Oral semaglutide starts at $249 per month and follows a similar dose escalation schedule: 3 mg for weeks one through four, 7 mg for weeks five through eight, and 14 mg maintenance thereafter. Oral tablets must be taken on an empty stomach to maximize absorption, whereas injections bypass the digestive system entirely.
Injection therapy typically achieves higher bioavailability—the amount of active drug your body actually uses—compared to oral tablets, because stomach acid and digestive enzymes do not break down injected medication. For patients seeking maximum appetite suppression or those with digestive disorders affecting tablet absorption, the injectable route often produces stronger results at equivalent nominal doses.
Managing Side Effects Across the Dose Escalation
Nausea, constipation, and mild stomach discomfort are common during the first two weeks at each new dose level. These effects typically resolve within five to seven days as your digestive system adapts. Staying hydrated, eating small frequent meals, and increasing dietary fiber can significantly reduce gastrointestinal symptoms without stopping treatment.
If side effects persist beyond one week or feel intolerable, your PlexusDx provider may recommend pausing at your current dose for an additional week before advancing. Skipping a dose or extending the interval between injections is never advised—instead, your provider will adjust your timeline to maintain therapeutic benefit while keeping you comfortable. Severe allergic reactions or persistent vomiting warrant immediate medical attention and discontinuation of the medication.
Genetic Testing to Personalize Your Semaglutide Response
PlexusDx's Precision Peptide Genetic Test identifies whether you carry genetic variants that influence GLP-1 receptor function, appetite hormone pathways, and metabolic regulation. Key variants such as GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609 predict how your body responds to semaglutide at different dose levels. This $99 add-on test (available after your first month of treatment) gives your provider data to optimize dosing and anticipate your individual response pattern.
Patients with certain GLP1R variants may achieve maximum appetite suppression at 1.7 mg rather than 2.4 mg, while others benefit from advancing to the full maintenance dose. Your genetic profile also reveals whether you are likely to experience stronger nausea at early doses or respond best to a slower escalation schedule. This precision approach removes guesswork and accelerates your path to sustainable weight loss.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
How often do I inject semaglutide during the dose escalation phase?
You inject semaglutide once per week throughout the entire escalation and maintenance phases. Each week you inject the dose prescribed for that week—0.25 mg in week one, 0.5 mg in week five, and so on. The schedule remains consistent; only the dose strength changes weekly or every four weeks depending on your provider's protocol.
Will I need a new semaglutide pen for each dose level?
Wegovy and other branded pens come prefilled at specific doses, requiring a new pen for each dose change. PlexusDx compounded semaglutide is customized to your current dose and supplied monthly, so you receive a fresh supply containing your exact prescribed strength without switching multiple devices.
What if I don't reach the 2.4 mg dose—is my treatment still effective?
Yes, many patients achieve their target weight loss at 1.7 mg or lower doses and maintain results without advancing further. Your provider will evaluate your progress and satisfaction at each dose level and determine whether increasing is necessary for continued benefit.
Can I stay on a lower dose long-term, or must I reach 2.4 mg?
Your effective dose is the one that produces the appetite suppression and weight loss you need while keeping side effects manageable. If 1.7 mg gives you the results you want, you can remain at that dose indefinitely. Treatment is tailored to your goals, not to a mandatory maximum.
How does the Precision Peptide Genetic Test predict my semaglutide dose response?
PlexusDx maps 14 appetite and metabolic pathways across 49 peptides, identifying your genetic variants in GLP1R, GIPR, FTO, and MC4R genes. These variants predict how strongly your GLP-1 receptors respond to the medication, helping your provider anticipate whether you'll respond optimally at lower doses or need higher amounts for maximum appetite control.
Is PlexusDx semaglutide FDA-approved?
PlexusDx compounded semaglutide is prepared by licensed 503A compounding pharmacies using FDA-approved semaglutide bulk powder. Compounded medications are not FDA-approved as finished products, but they are made under strict pharmacy standards and quality oversight. Your provider can discuss the regulatory framework and safety profile with you.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What Is in Ozempic Injection? Understanding Its Composition and Benefits
Is Gas a Side Effect of Zepbound? Understanding the Implications